Shares of Poseida Therapeutics, which develops cell and gene therapies for cancers and genetic diseases, skyrocketed nearly 230% on Tuesday, November 26. The surge came after the <a href="https://investors.poseida.com/news-releases/news-release-details/poseida-therapeutics-inc-announces-agreement-be-acquired-roche?utm_source=in_materials">announcement</a> of its acquisition by pharmaceutical giant Roche, with the deal valuing Poseida at $1.5 billion — triple its highest market value in the last year.

Poseida Therapeutics, cell therapy maker, triples on Nasdaq after being acquired by Roche

On Monday, October 7, shares of the biotech company Scholar Rock soared close to 362% following the <a href="https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-apitegromab-meets-primary-endpoint-phase-3">announcement</a> that its lead candidate, apitegromab, a treatment for spinal muscular atrophy (SMA), had demonstrated clinically significant results in the final, phase III trial. Currently, there are only three approved drugs for this genetic disease, with the SMA market <a href="https://www.biospace.com/spinal-muscular-atrophy-market-size-to-reach-us-13-0-billion-by-2034-impelled-by-increased-popularity-of-gene-therapy#:~:text=The%20spinal%20muscular%20atrophy%20market,14.28%25%20during%202024%2D2034.">estimated</a> at $3 billion in 2023.

#: 2

Poseida Therapeutics, cell therapy maker, triples on Nasdaq after being acquired by Roche

Scholar Rock stock skyrockets on positive trial data for its SMA drug